Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS 2922 antisense compound: Began Phase III trial

One will compare time to disease progression with ISIS 2922 plus ganciclovir with ganciclovir alone.

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE